Alternate Dosing Regimens of BG00012 in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-02-01

Study Completion Date

2011-03-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, tolerability, and PK of different doses and dosing regimens of BG00012 administered with and without ASA compared to placebo

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

NCT01568112

Healthy

COMPLETED PHASE3

Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome

NCT00272311

Cardiovascular Diseases Metabolic Syndrome X Atherosclerosis

COMPLETED PHASE4

An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants

NCT03341390

Healthy Volunteers

COMPLETED PHASE1

Aspirin Dose and Atherosclerosis in Patients With Heart Disease

NCT00272337

Cardiovascular Diseases Atherosclerosis Myocardial Infarction

COMPLETED PHASE4

Effect of Aspirin on Hemostatic and Vascular Function After Live Fire Fighting

NCT01276691

Cardiovascular Risk Factor C.Medical Procedure; Vascular, Functional or Late Electrolyte and Fluid Balance Conditions

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Preclinical safety margins for BG00012 allow for a maximum daily dose of 720 mg daily. The study will use a variety of clinical scales, including a flushing scale derived from a validated questionnaire \[Norquist 2007\], to better understand the safety and tolerability of several doses and dosing regimens of BG00012 up to a total daily dose of 720 mg. The etiology of BG00012-induced flushing will be assessed by collecting relevant biomarker data and the impact of ASA on flushing will be evaluated. Assessments relating to GI symptoms will also be performed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BG00012 plus ASA

Group Type EXPERIMENTAL

Dimethyl Fumarate (BG00012)

Intervention Type DRUG

Aspirin

Intervention Type DRUG

BG00012 plus ASA matching placebo

Group Type EXPERIMENTAL

Dimethyl Fumarate (BG00012)

Intervention Type DRUG

ASA matching placebo

Intervention Type DRUG

BG00012 Placebo plus ASA

Group Type PLACEBO_COMPARATOR

Aspirin

Intervention Type DRUG

BG00012 matching placebo

Intervention Type DRUG

BG00012 Placebo plus ASA matching placebo

Group Type EXPERIMENTAL

BG00012 matching placebo

Intervention Type DRUG

ASA matching placebo

Intervention Type DRUG

BG00012

modified dose regimen

Group Type EXPERIMENTAL

Dimethyl Fumarate (BG00012)

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dimethyl Fumarate (BG00012)

Intervention Type DRUG

Aspirin

Intervention Type DRUG

BG00012 matching placebo

Intervention Type DRUG

ASA matching placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
* Aged 18 to 55 years old, inclusive, at the time of informed consent.
* Must be in good health, as determined by the Investigator, based on medical history and screening evaluations.
* Must have a body mass index of 18 to 34 kg/m2, inclusive.
* Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Exclusion Criteria

* History of any clinically significant cardiac, endocrinologic, GI, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
* History of malignant disease, including solid tumors and hematologic malignancies (except basal cell and squamous cell carcinomas of the skin that have been completely excised and are considered cured).
* Serious infection (e.g., pneumonia, septicemia) as determined by the Investigator within the 3 months prior to Day 1.
* Diarrhea, constipation, abdominal pain, flushing, or nausea within 28 days prior to Day 1.
* History of severe allergic or anaphylactic reactions. Additionally, subjects with a history of intolerance to ASA or non-steroidal anti-inflammatory drugs (NSAIDS) must be excluded.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes